MAGE-A4/MAGE-A8-targeted TCR-based bispecific T cell engager in recurrent and/or refractory solid tumors: a phase 1 trial. - Wermke M; Ochsenreither S; Jaeger D; Becker H; Bleckmann A; Bozorgmehr F; Chatterjee M; Groepper S; Haenel M; Hecker JS; Häring MF; Heudobler D; et al. (Nature medicine, 2026)